Fragile X syndrome

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
3 Unique sponsors
3 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Phase III: 1 Phase II: 2 Phase I: 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • Harmony Biosciences Management Inc. Commercial
    CANNABIDIOL
    2024-513888-99-00 1 country 2023 n=7 Orphan
    Ended

Phase II

2 trials
  • Connecta Therapeutics S.L. Commercial
    2-[4-[3-(METHYLAMINO)-1-PHENYLPROPOXY]PHENYL]ETHANOL HYDROCHLORIDE
    2025-522972-97-00 1 country 2026 n=30 Orphan
    Recruiting
  • Mirum Pharmaceuticals Inc. Commercial
    MRM-3379
    2025-523738-21-00 1 country n=15
    Pending

Phase I

1 trial
  • Connecta Therapeutics S.L. Commercial
    IMP not specified
    2022-502209-13-01 1 country 2023 n=68
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Connecta Therapeutics S.L. Commercial 2 Phase I, Phase II 1
Mirum Pharmaceuticals Inc. Commercial 1 Phase II 0
Harmony Biosciences Management Inc. Commercial 1 Phase III 0
New trials by year
2023
2
2026
1
← All indication landscapes